medigraphic.com
Colegio de Medicina Interna de México.

2008, Number 1

<< Back Next >>

Med Int Mex 2008; 24 (1)

Historic view and epidemiological aspects of Parkinson’s disease

García S, Sauri SS, Meza DE, Lucino CJ

Language: Spanish
References: 58
Page: 28-37
PDF size: 286.25 Kb.


ABSTRACT

Parkinson’s disease is a neurodegenerative and progressive disease that at this moment has no curative treatment. We reviewed, from January 1970 to July 2007, these items: “Parkinson’s disease”, “PD”, “parkinsonism”, “epidemiology”, “cohort study”, “prevalence”, “incidence”, “risk factors”, pesticide”, “diet”, “coffee”, “smoking”, “alcohol”, “inflammation”, “susceptibility genes”, “mortality”, “dementia”, and “prognosis” in MedLine and PubMed data bases. It was chosen solid methodological papers, specially meta-analyses, and Google search was used for historical aspect of Parkinson’s disease. Important and enough information to get the objectives of this paper was found.


REFERENCES

  1. Siderowf A. Parkinson’s disease: clinical features, epidemiology and genetics. Neurol Clin 2001;19(3):565-78.

  2. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s Disease. J Neurol Neurosurg Psychiatry 1997;62(1):10-5.

  3. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis inparkinsonism — a prospective study. Can J Neurol Sci 1991;18:275-8.

  4. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50(2):140-8.

  5. Jendroska K, Olasode BJ, Daniel SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994;344(8926):882- 3.

  6. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-20.

  7. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology 1999;52(2):302-8.

  8. Albin RL. Parkinson’s disease: background, diagnosis, and initial management. Clin Geriatr Med 2006;22(4):735-51.

  9. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16(3):278-82.

  10. Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ. Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA. Chin Med J (Engl) 1991;104(11):960-4.

  11. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142(8):820-7.

  12. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55(9):1358-63.

  13. Chen RC, Chang SF, Su CL, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001;57(9):1679-86.

  14. Benito-León J, Bermejo-Pareja F, Morales-González JM, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004;62(5):734-41.

  15. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63(7):1240-4.

  16. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38(7):1031-4.

  17. Trenkwalder C, Schwarz J, Gebhard J, et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995;52(10):1017-22.

  18. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354(9192):1771-5.

  19. Moghal S, Rajput AH, D’Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13(4):175-8.

  20. Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J. Prevalence of Parkinson’s disease in lower Aragon, Spain. Mov Disord 1999;14(4):596-604.

  21. Yanagisaw N. Natural history of Parkinson’s disease: From dopamine to multiple system involvement. Parkinsonism and Related Disorders 2006 (in press).

  22. Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord 1995;10(3):250-6.

  23. Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67(3):300-7.

  24. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology 1993;43(10):1918-26.

  25. Phillips NJ, Reay J, Martyn CN. Validity of mortality data for Parkinson’s disease. J Epidemiol Community Health 1999;53((9):587-8.

  26. Maraganore DM, Anderson DW, Bower JH, McDonell SK, Rocca WA. Autopsy patterns for Parkinson‘s disease and related disorders in Olmsted County, Minnesota. Neurology 1999;53(6):1342-4.

  27. Poewe W. The Sydney multicentre study of Parkinson’s disease [editorial]. J Neurol Neurosurg Psychiatry 1999;67(3):280-1.

  28. Lang A, Lozano A. Parkinson´s Disease. First of two parts. N Engl J Med 1998;339(15):1044-53.

  29. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.

  30. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 1996;119(Pt 2):585-91.

  31. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5(6):525-35.

  32. Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42(7):1328-35.

  33. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson’s disease? J Neurol Neurosurg Psychiatry 1996;61(1):4-16.

  34. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A metaanalysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology 2000;21(4): 435-40.

  35. Petrovitch H, Ross GW, Abbott RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 2002;59(11):1787-92.

  36. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000;3(12):1301-6.

  37. Greenamyre JT, Hastings TG. Biomedicine. Parkinson’sdivergent causes, convergent mechanisms. Science 2004;304((5674):1120-2.

  38. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 2002;8(5):297-309.

  39. Paganini-Hill A. Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001;20(2):118-24.

  40. Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol 2003;54(2):170-5.

  41. Fall PA, Fredrikson M, Axelson O, Granérus AK. Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov Disord 1999;14(1):28-37.

  42. Jiménez-Jiménez FJ, Mateo D, Giménez-Roldán S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord 1992;7(4):339-44.

  43. Stocchi F, Olanow CW. Neuroprotection in Parkinson’s disease: clinical trials. Ann Neurol 2003;53(suppl 3):S87-97.

  44. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002;59(8):1161-9.

  45. Farooqui AA, Horrocks LA. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell Mol Neurobiol 1998;18(6):599-608.

  46. Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease: The Rotterdam Study. Arch Neurol 1997;54(6):762-5.

  47. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol 1999;28(6):1102-9.

  48. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000;18(4-5): 383-99.

  49. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord 1999;14(1):21-27.

  50. Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol 2004;160(4):368-75.

  51. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue? Neurology 1995;45(6):1041-51.

  52. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol 1994;139(12):1129-38.

  53. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 2002;52(3):276-84.

  54. Hellenbrand W, Seidler A, Robra BP, et al. Smoking and Parkinson’s disease: a case-control study in Germany. Int J Epidemiol 1997;26(2):328-39.

  55. Quik M. Smoking, nicotine and Parkinson’s disease. Trends Neurosci 2004;27(9):561-8.

  56. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004;10(suppl 1):S3-7.

  57. de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005;57(6):927-30.

  58. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003;72(4):804-11.




2020     |     www.medigraphic.com